Patents Assigned to Indivior UK Limited
-
Patent number: 10239870Abstract: The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.Type: GrantFiled: May 9, 2018Date of Patent: March 26, 2019Assignee: Indivior UK LimitedInventors: Susanna Cremonesi, Fabrizio Micheli, Teresa Semerano, Luca Tarsi
-
Patent number: 10198218Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: GrantFiled: December 28, 2017Date of Patent: February 5, 2019Assignee: Indivior UK LimitedInventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Patent number: 10172849Abstract: This disclosure relates to a buprenorphine sustained release delivery system for treatment of conditions ameliorated by buprenorphine compounds. The sustained release delivery system includes a flowable composition containing a suspension of buprenorphine, a metabolite, or a prodrug thereof.Type: GrantFiled: March 3, 2016Date of Patent: January 8, 2019Assignee: INDIVIOR UK LIMITEDInventors: Richard L. Norton, Mingxing Zhou
-
Patent number: 10149912Abstract: The invention provides a controlled release biodegradable polymer formulation adapted for administering bioactive agents, such as therapeutic proteins, to a patient through implantation of a bolus that forms a depot within the patient's body tissues. The formulation includes a dehydrated inclusion complex of the bioactive agent within a hydrogel. A method of forming the inventive formulation is also provided, as well as a method for using the formulation in the treatment of a malcondition in a patient in need thereof.Type: GrantFiled: October 17, 2016Date of Patent: December 11, 2018Assignee: Indivior UK LimitedInventors: Eric Dadey, Andrew Watkins
-
Patent number: 10058554Abstract: An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having Cmax to Cmin ratio less than 200 and lag time less than 0.2.Type: GrantFiled: February 2, 2017Date of Patent: August 28, 2018Assignee: Indivior UK LimitedInventors: Andrew S. Luk, Gunjan H. Junnarkar, Guohua Chen
-
Patent number: 10022367Abstract: The disclosure provides extended release pharmaceutical formulations comprising an opioid, particularly buprenorphine, a biocompatible organic solvent, and, optionally, a glycol, for use in the treatment of pain or opioid dependence. The pharmaceutical formulations are in the form of a pharmaceutical solution.Type: GrantFiled: March 9, 2015Date of Patent: July 17, 2018Assignee: Indivior UK LimitedInventors: Mingxing Zhou, Richard L. Norton
-
Patent number: 10010612Abstract: The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite, or a prodrug thereof.Type: GrantFiled: February 13, 2008Date of Patent: July 3, 2018Assignee: Indivior UK LimitedInventors: Eric Dadey, Qi Li, Christopher Lindemann
-
Patent number: 10000477Abstract: The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.Type: GrantFiled: October 30, 2015Date of Patent: June 19, 2018Assignee: Indivior UK LimitedInventors: Susanna Cremonesi, Fabrizio Micheli, Teresa Semeraro, Luca Tarsi
-
Publication number: 20170354653Abstract: The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.Type: ApplicationFiled: November 6, 2015Publication date: December 14, 2017Applicants: Indivior UK Limited, Indivior UK LimitedInventor: Azmi Nasser
-
Patent number: 9827241Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: GrantFiled: June 14, 2017Date of Patent: November 28, 2017Assignee: Indivior UK LimitedInventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Patent number: 9782402Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: GrantFiled: October 25, 2016Date of Patent: October 10, 2017Assignee: Indivior UK LimitedInventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Patent number: 9687454Abstract: The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.Type: GrantFiled: January 6, 2016Date of Patent: June 27, 2017Assignee: Indivior UK LimitedInventors: Garry L. Myers, Samuel D. Hilbert, Bill J. Boone, Beuford Arlie Bogue, Pradeep Sanghvi, Madhusudan Hariharan
-
Patent number: 9498432Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: GrantFiled: January 13, 2016Date of Patent: November 22, 2016Assignee: Indivior UK LimitedInventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Patent number: 9486531Abstract: The invention provides a controlled release biodegradable polymer formulation adapted for administering bioactive agents such as therapeutic proteins to a patient through implantation of a bolus that forms a depot within the patient's body tissues. The formulation includes a dehydrated inclusion complex of the bioactive agent within a hydrogel, wherein the hydrogel can comprise a polymerized polyalkyleneglycolyl diacrylate, and, optionally, polyalkyleneglycolyl monoacrylates, including methacrylates. Alternatively, the hydrogel can comprise hyaluronic acid, chitosan, agarose, polyvinylacetate, polyvinylpyrrolide, or polyvinylalcohol nanoparticles. The bioactive agent can be a macromolecular material, such as a protein. A method of forming the inventive formulation is also provided, as well as a method for using the formulation in the treatment of a malcondition in a patient in need thereof.Type: GrantFiled: June 3, 2009Date of Patent: November 8, 2016Assignee: INDIVIOR UK LIMITEDInventors: Eric Dadey, Andrew (Drew) Watkins
-
Publication number: 20160184296Abstract: This disclosure relates to a buprenorphine sustained release delivery system for treatment of conditions ameliorated by buprenorphine compounds. The sustained release delivery system includes a flowable composition containing a suspension of buprenorphine, a metabolite, or a prodrug thereof.Type: ApplicationFiled: March 3, 2016Publication date: June 30, 2016Applicant: Indivior UK LimitedInventors: Richard L. Norton, Mingxing Zhou
-
Patent number: 9295645Abstract: This disclosure relates to a buprenorphine sustained release delivery system for treatment of conditions ameliorated by buprenorphine compounds. The sustained release delivery system includes a flowable composition containing a suspension of buprenorphine, a metabolite, or a prodrug thereof.Type: GrantFiled: June 6, 2011Date of Patent: March 29, 2016Assignee: Indivior UK LimitedInventors: Richard L. Norton, Mingxing Zhou
-
Patent number: 9272044Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: GrantFiled: January 30, 2015Date of Patent: March 1, 2016Assignee: Indivior UK LimitedInventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Patent number: 9186413Abstract: The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite, or a prodrug thereof.Type: GrantFiled: September 18, 2014Date of Patent: November 17, 2015Assignee: Indivior UK LimitedInventor: Eric Dadey
-
Patent number: 9180197Abstract: The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite, or a prodrug thereof.Type: GrantFiled: September 18, 2014Date of Patent: November 10, 2015Assignee: Indivior UK LimitedInventor: Eric Dadey